Health Winners & Losers: Halozyme

J&J shares edged up 35 cents, or 0.5%, to $64.69.

Also, Teva Pharmaceutical (TEVA Quote) said Monday post-close that the FDA granted it approval to market a generic version of Janssen's antipsychotic agent Risperdal and that shipment of the products has begun. Because it was the first to file a generic version, it receives a 180-day period of marketing exclusivity. Teva said the brand products had sales of $2.6 billion in the U.S. for the 12 months ended March 31, 2008, based on prescription data. Shares rose $1.19, or 2.6%, to $46.99.

Qiagen (QGEN Quote) said Tuesday that it acquired Corbett Life Science for $66 million in cash, $4 million in restricted common stock, and up to $65 million tied to future milestones in the next four years. The company expects one-time acquisition charges of 2 cents a share in the third quarter and expects the acquisition will add roughly $14 million in revenue in the second half of 2008 and roughly $40 million in 2009. Qiagen shares edged up 27 cents, or 1.3%, to $20.40.